Bristol-Myers Squibb Company (BMY) vs Novo Nordisk A/S (NVO)
A side-by-side comparison of Bristol-Myers Squibb Company and Novo Nordisk A/S across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.
BMY
Bristol-Myers Squibb Company
$63.60HealthcareDelayed quote: Sep 15, 2026, 10:45 AM EDT
NVO
Novo Nordisk A/S
$42.58HealthcareDelayed quote: Sep 15, 2026, 10:45 AM EDT
Total return — BMY vs NVO
growth of $100 · dividends reinvested · last 10yBMY +60.1% (+4.8%/yr)NVO +135.8% (+9.0%/yr)NVO compounded faster over this window
BMY NVO
BMY vs NVO: by the numbers
- •NVO is the larger company ($189.08B vs $129.92B market cap).
- •NVO trades at the lower trailing earnings multiple (10.49 vs 14.01 P/E), one valuation lens rather than an overall verdict.
- •NVO converts more revenue to profit (35.33% vs 18.87% net margin).
- •NVO grew revenue faster over the past five years (19.76% vs 2.08% CAGR).
- •NVO pays the higher dividend yield (4.17% vs 3.94%).
Metrics side by side
Valuation
| Metric | BMY | NVO |
|---|---|---|
| P/E ratio | 14.01 | 10.49 |
| Forward P/E | 9.18 | N/A |
| P/S ratio | 2.64 | 3.70 |
| P/B ratio | 5.82 | 5.61 |
| EV / EBITDA | 9.70 | 7.77 |
| FCF yield | 8.81% | 3.94% |
Profitability
| Metric | BMY | NVO |
|---|---|---|
| Gross margin | 70.16% | 80.64% |
| Operating margin | 28.27% | 43.10% |
| Net margin | 18.87% | 35.33% |
| ROE | 41.59% | 53.50% |
| ROIC | 15.47% | 30.21% |
Dividends
| Metric | BMY | NVO |
|---|---|---|
| Dividend yield | 3.94% | 4.17% |
| Payout ratio | 55.29% | 44.27% |
Growth (annualized)
| Metric | BMY | NVO |
|---|---|---|
| Revenue CAGR (5Y) | 2.08% | 19.76% |
| EPS CAGR (5Y) | 9.38% | 19.59% |
| FCF CAGR (5Y) | -0.95% | -1.45% |
| Total return CAGR (5Y) | 4.35% | -0.65% |
Frequently asked
- Which has the lower trailing P/E, BMY or NVO?
- NVO has the lower trailing P/E: BMY trades at 14.01 and NVO at 10.49. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BMY or NVO?
- Over the past five years, NVO grew revenue faster — BMY at a 2.08% CAGR versus NVO at 19.76%.
- Does BMY or NVO pay a bigger dividend?
- BMY yields 3.94% and NVO yields 4.17% based on trailing dividends and the latest price.
- Is BMY or NVO more profitable?
- NVO runs the higher net margin — BMY at 18.87% versus NVO at 35.33%.
- How have BMY and NVO total returns compared?
- Over the past 10 years, BMY delivered 4.99% and NVO delivered 9.46% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bristol-Myers Squibb P/E ratioNovo Nordisk A/S P/E ratioBristol-Myers Squibb dividend yieldNovo Nordisk A/S dividend yieldBristol-Myers Squibb ROENovo Nordisk A/S ROEBristol-Myers Squibb operating marginNovo Nordisk A/S operating marginBristol-Myers Squibb revenue growthNovo Nordisk A/S revenue growthBristol-Myers Squibb free cash flowNovo Nordisk A/S free cash flow
Bristol-Myers Squibb & Novo Nordisk A/S appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.